Charles River Laboratories International (NYSE:CRL) managed to eke out gains of 0.9% in intraday trade. The share price increased by 0.75 points to $83.64. Till last observation, the net money flow was recorded at a negative $(-0.44) million. The total inflow of $0.09 million in upticks was completely overshadowed by an outflow of $0.53 million in downticks, giving the up/down ratio a value of 0.17. The shares have seen a change of 1.89% in the past week.
The stock has recorded a 20-day Moving Average of 2.72% and the 50-Day Moving Average is 0.1%. The company shares have rallied 11.1% in the past 52 Weeks. On June 2, 2016 The shares registered one year high of $87.95 and one year low was seen on October 6, 2015 at $59.99. The 50-day moving average is $83.8 and the 200 day moving average is recorded at $78.11. S&P 500 has rallied 1.93% during the last 52-weeks.
Charles River Laboratories International (NYSE:CRL): The stock opened at $82.82 on Tuesday but the bulls could not build on the opening and the stock topped out at $83.65 for the day. The stock traded down to $82.27 during the day, due to lack of any buying support eventually closed down at $82.74 with a loss of -0.18% for the day. The stock had closed at $82.89 on the previous day. The total traded volume was 342,840 shares.
Currently the company Insiders own 2.3% of Charles River Laboratories International shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -11.85% . Institutional Investors own 98.18% of Charles River Laboratories International shares. During last six month period, the net percent change held by insiders has seen a change of -3.16%. On the companys insider trading activities,The officer (SVP, Chief Accounting Officer) of Charles River Laboratories International Inc, Crowley John J sold 1,913 shares at $85 on May 24, 2016. The Insider selling transaction had a total value worth of $162,605. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Charles River Laboratories International, Inc. is a full service, early stage contract research company. The Company offers research models for the research and development of new drugs, devices and therapies. It develops a portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP that support the clients from target identification through preclinical development. The Company operates through three segments: Research Models and Services (RMS), which supplies research models to the drug development industry; Discovery and Safety Assessment (DSA), which provides services that enables the clients to outsource their drug discovery research, critical, regulatory-required safety assessment testing and related drug discovery and development activities, and Manufacturing Support (Manufacturing), which is involved in the production and release of products manufactured by the clients.